Aradigm Corporation Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis at the North American Cystic Fibrosis Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB: ARDM) (“Aradigm”) today announced it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida.